BACKGROUND: Epithelial ovarian cancer (EOC) is the fifth leading cause of cancer-related death in females and leading gynecologic cause of cancer-related death. Despite the identification of a number of serum biomarkers, methods to identify early-stage disease and predict prognosis remain scarce. We have evaluated two biologically connected serum biomarkers, serum leukocyte protease inhibitor (SLPI) and progranulin (PGRN). METHODS: Two-hundred frozen plasma samples were acquired from the Mayo Clinic Biospecimen Repository for Ovarian Cancer Research. Samples were obtained from 50 patients with benign conditions, 50 with American Joint Committee on Cancer (AJCC) stage I and II EOC, and 100 with AJCC stage III and IV EOC. Samples were obtained before surgical resection of a mass and were analyzed for absolute levels of SLPI and PGRN using ELISA assays. Receiver-operator characteristic curves were generated for SLPI and PGRN. Median follow-up was 48 months. RESULTS: Absolute levels of SLPI were significantly elevated in patients with EOC compared with benign disease and predicted the presence of EOC (AUC of 0.812; P = 0.04); SLPI remained elevated in the subset of patients with normal CA-125. PGRN levels were not significantly increased in patients with early-stage or late-stage EOC as a whole, but an increase in PGRN levels was associated with decreased overall survival in advanced EOC. CONCLUSIONS: SLPI levels are elevated in EOC, and SLPI shows promise as a diagnostic biomarker for patients with both elevated and normal CA-125 levels. An increase in PGRN is associated with decreased overall survival. IMPACT: SLPI is elevated in EOC and warrants investigation in a screening study in women at risk for EOC.
BACKGROUND:Epithelial ovarian cancer (EOC) is the fifth leading cause of cancer-related death in females and leading gynecologic cause of cancer-related death. Despite the identification of a number of serum biomarkers, methods to identify early-stage disease and predict prognosis remain scarce. We have evaluated two biologically connected serum biomarkers, serum leukocyte protease inhibitor (SLPI) and progranulin (PGRN). METHODS: Two-hundred frozen plasma samples were acquired from the Mayo Clinic Biospecimen Repository for Ovarian Cancer Research. Samples were obtained from 50 patients with benign conditions, 50 with American Joint Committee on Cancer (AJCC) stage I and II EOC, and 100 with AJCC stage III and IV EOC. Samples were obtained before surgical resection of a mass and were analyzed for absolute levels of SLPI and PGRN using ELISA assays. Receiver-operator characteristic curves were generated for SLPI and PGRN. Median follow-up was 48 months. RESULTS: Absolute levels of SLPI were significantly elevated in patients with EOC compared with benign disease and predicted the presence of EOC (AUC of 0.812; P = 0.04); SLPI remained elevated in the subset of patients with normal CA-125. PGRN levels were not significantly increased in patients with early-stage or late-stage EOC as a whole, but an increase in PGRN levels was associated with decreased overall survival in advanced EOC. CONCLUSIONS:SLPI levels are elevated in EOC, and SLPI shows promise as a diagnostic biomarker for patients with both elevated and normal CA-125 levels. An increase in PGRN is associated with decreased overall survival. IMPACT: SLPI is elevated in EOC and warrants investigation in a screening study in women at risk for EOC.
Authors: Sasa Kadija; Aleksandar Stefanovic; Katarina Jeremic; Milos M Radojevic; Ljubinka Nikolic; Ivanka Markovic; Jasmina Atanackovic Journal: Int J Gynecol Cancer Date: 2012-02 Impact factor: 3.437
Authors: A Ruibal; G Encabo; E Martinéz-Miralles; C Murcia; J A Capdevila; A Salgado; J M Martinéz-Vasquéz Journal: Bull Cancer Date: 1984 Impact factor: 1.276
Authors: Ingegerd Hellström; John Raycraft; Martha Hayden-Ledbetter; Jeffrey A Ledbetter; Michèl Schummer; Martin McIntosh; Charles Drescher; Nicole Urban; Karl Erik Hellström Journal: Cancer Res Date: 2003-07-01 Impact factor: 12.701
Authors: Nick Devoogdt; Gholamreza Hassanzadeh Ghassabeh; Jing Zhang; Lea Brys; Patrick De Baetselier; Hilde Revets Journal: Proc Natl Acad Sci U S A Date: 2003-05-05 Impact factor: 11.205
Authors: Amro M S El-Ghammaz; Mohamed O Azzazi; Nevine Mostafa; Hany M Hegab; Amir A Mahmoud Journal: Clin Exp Med Date: 2020-01-31 Impact factor: 3.984
Authors: Fabian Arechavaleta-Velasco; Carlos Eduardo Perez-Juarez; George L Gerton; Laura Diaz-Cueto Journal: Med Oncol Date: 2017-11-07 Impact factor: 3.064
Authors: Ramouna Voshtani; Mei Song; Huan Wang; Xiaoqi Li; Wei Zhang; Mojdeh S Tavallaie; Wenjun Yan; Joseph Sun; Fang Wei; Xiaojing Ma Journal: Cancer Lett Date: 2019-09-03 Impact factor: 8.679
Authors: Yanli Zhang; Jamie Sui-Lam Kwok; Pui-Wah Choi; Minghua Liu; Junzheng Yang; Margit Singh; Shu-Kay Ng; William R Welch; Michael G Muto; Stephen Kw Tsui; Stephen P Sugrue; Ross S Berkowitz; Shu-Wing Ng Journal: Oncotarget Date: 2016-03-08